Verition Fund Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Verition Fund Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-397,603	Closed	-$4.12M	–	2730
2023 Q1	$4.12M	Hold	397,603	–	–	0.06%	438
2022 Q4	$3.97M	Hold	397,603	–	–	0.06%	397
2022 Q3	$3.98M	Hold	397,603	–	–	0.04%	530
2022 Q2	$3.96M	Hold	397,603	–	–	0.08%	348
2022 Q1	$3.93M	Hold	397,603	–	–	0.05%	512
2021 Q4	$3.97M	Hold	397,603	–	–	0.03%	472
2021 Q3	$3.98M	Sell	397,603 -89	-0%	-$889	0.03%	347
2021 Q2	$4.05M	Hold	397,692	–	–	0.04%	288
2021 Q1	$4.06M	Buy	+397,692	New	+$4.24M	0.05%	236

Verition Fund Management's EUCRU Position: Q2 2023 in Review

Verition Fund Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q2 2023, closing a stake of 397,603 shares — an estimated $4.12M sold.

Verition Fund Management first reported a position in EUCRU in Q1 2021 and held it in 9 quarters. The position peaked at $4.12M in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCRU as of Q2 2023.

Verition Fund Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q2 2023 after selling out during the quarter.
Verition Fund Management sold 397,603 Eucrates Biomedical Acquisition Corp. Unit shares in Q2 2023, an estimated $4.12M.
Verition Fund Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q1 2021 and held it in 9 quarters.
Verition Fund Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $4.12M in Q1 2023.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q2 2023.

Based on Verition Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.